Abstract | INTRODUCTION: METHODS: Stored plasma samples from patients with SCD recruited to two clinical studies were analyzed. One study encompasses 488 patient samples with SCD (HbSS, HbSβ0 and HbSC) at steady state and 52 race-matched, healthy controls. The other study included paired plasma samples during steady state and acute pain crisis from (HbSS) patients with SCD. Plasma GlycA was measured using a proton NMR on the Vantera® Clinical Analyzer. We performed analysis comparing patients with SCD, healthy controls, and paired samples analysis. RESULTS: The mean plasma GlycA level was lower in SCD compared with healthy controls (324.6 ± 70.4 μmol/L vs. 386.3 ± 74.6 μmol/L, P < 0.0001). Within the same patient, mean plasma GlycA during acute pain crisis was lower than steady state, although the difference was not significant (300.5 ± 36.3 μmol/L vs 314.2 ± 34.8 μmol/L, P = 0.020). Plasma GlycA correlated inversely with serum LDH (P = 0.009). CONCLUSION:
|
Authors | Julie K Weisman, Daveena Meeks, Laurel Mendelsohn, Alan T Remaley, Maureen Sampson, Darlene T Allen, Jim Nichols, Arun S Shet, Swee Lay Thein |
Journal | International journal of laboratory hematology
(Int J Lab Hematol)
Vol. 40
Issue 6
Pg. 704-709
(Dec 2018)
ISSN: 1751-553X [Electronic] England |
PMID | 30152174
(Publication Type: Comparative Study, Journal Article)
|
Copyright | © 2018 The Authors. International Journal of Laboratory Hematology Published by John Wiley & Sons Ltd. |
Chemical References |
- Biomarkers
- Glycation End Products, Advanced
|
Topics |
- Adult
- Anemia, Sickle Cell
(blood)
- Biomarkers
(blood)
- Female
- Glycation End Products, Advanced
(blood)
- Humans
- Inflammation
(blood)
- Male
- Middle Aged
- Nuclear Magnetic Resonance, Biomolecular
|